Sézary syndrome

Sézary syndrome is classified separately from mycosis fungoides, although both are cutaneous T-cell lymphomas. Diagnosis combines widespread skin findings, a malignant T-cell population in blood and appropriate pathological and molecular assessment.

The blood involvement makes this a systemic disease from the outset. A rash and circulating atypical cells alone are not sufficient for self-diagnosis; specialist tests distinguish it from inflammatory skin disorders and other lymphomas.

Genetic changes allow an abnormal mature T-cell clone to grow and persist. The initiating cause is usually unknown. These changes are generally acquired in the malignant cells.

The condition is not an infection and is not contagious. It should not be described as the inevitable last stage of every case of mycosis fungoides.

The skin can become red or inflamed over much of the body, intensely itchy, peeling or painful. Thickened palms and soles, enlarged lymph nodes, hair changes and nail changes may occur.

Skin-barrier damage and immune dysfunction increase infection risk. Itching and discomfort can substantially disturb sleep and daily life. The severity and combination of symptoms differ among people.

Treatment usually includes systemic therapy, often combined with skin-directed measures. Options include extracorporeal photopheresis, retinoids, interferon, mogamulizumab and other targeted agents according to the disease pattern, previous treatment and availability.

Photopheresis treats a collected portion of the patient’s white blood cells with a light-sensitive medicine and ultraviolet light before returning them. It is a treatment using the patient’s own cells, not a donor stem cell transplant.

Allogeneic transplantation may be considered for eligible patients with an appropriate disease response and risk-benefit balance. It can produce durable remission, but relapse and serious complications remain possible. Previous medicines, particularly mogamulizumab, can influence transplant planning and graft-versus-host disease risk.

Daily skin care, treatment for itch and infection prevention may remain important through several lines of therapy. Clinical care should address sleep, nutrition, mobility and emotional strain as well as blood and skin measurements.

Before transplant, discussions include the time needed near the center, caregiver support and longer-term follow-up. Afterward, careful assessment is needed when skin symptoms change because several complications can resemble the original disease.

A donor provides blood-forming cells only if allogeneic transplantation is chosen. This may come from an unrelated registry volunteer, a relative or another appropriate graft source.

Donor evaluation can begin while other treatment controls disease. Joining a registry supports that possibility, but it should not imply that every person with Sézary syndrome is medically eligible for transplantation or has no useful treatment without it.

What is the exact diagnosis or subtype? What is the goal of each treatment option? If transplant is being considered, why does it fit this situation, which cells would be used and what are the alternatives?